Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews.
Lauren J LeeChristina S KwonAnna ForsytheCarla M MamoloElizabeth T MastersIra A JacobsPublished in: ClinicoEconomics and outcomes research : CEOR (2020)
NMIBC has a considerable symptomatic, HRQoL, and economic burden. Symptoms persisted and HRQoL worsened despite intravesical BCG treatment. NMIBC is a costly disease, with higher healthcare costs associated with increased risk of disease progression and recurrence. There is a high unmet need for safe and effective treatments that reduce the risk of disease progression and recurrence, provide symptomatic relief, and improve HRQoL for patients.
Keyphrases
- muscle invasive bladder cancer
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- systematic review
- prognostic factors
- peritoneal dialysis
- free survival
- randomized controlled trial
- patient reported outcomes
- depressive symptoms
- replacement therapy
- smoking cessation
- health information
- urinary tract